These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38878007)

  • 21. Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction.
    Tan YJ; Linden S; Ong SC
    PLoS One; 2024; 19(8):e0305257. PubMed ID: 39178204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
    Liao CT; Yang CT; Toh HS; Chang WT; Chang HY; Kuo FH; Lee MC; Hua YM; Tang HJ; Strong C; Ou HT
    Cardiovasc Diabetol; 2021 Oct; 20(1):204. PubMed ID: 34627231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
    Davis JA; Booth D; McEwan P; Solomon SD; McMurray JJV; de Boer RA; Comin-Colet J; Bachus E; Chen J
    Eur J Heart Fail; 2024 Mar; 26(3):664-673. PubMed ID: 38509642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
    Koufakis T; Mustafa OG; Tsimihodimos V; Ajjan RA; Kotsa K
    Drugs; 2021 Aug; 81(12):1365-1371. PubMed ID: 34232488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
    Pérez MS; Rodríguez-Capitán J; Requena-Ibáñez JA; Santos-Gallego CG; Urooj Zafar M; Escolar G; Mancini D; Mitter S; Lam D; Contreras JP; Fergus I; Atallah-Lajam F; Abascal V; Lala A; Moreno P; Moss N; Lerakis S; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2023 Jun; ():. PubMed ID: 37318685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.
    Sridhar VS; Bhatt DL; Odutayo A; Szarek M; Davies MJ; Banks P; Pitt B; Steg PG; Cherney DZI
    Clin J Am Soc Nephrol; 2024 May; 19(5):557-564. PubMed ID: 38277468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
    Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
    Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.
    Alsumali A; Djatche LM; Briggs A; Liu R; Diakite I; Patel D; Wang Y; Lautsch D
    Pharmacoeconomics; 2021 Nov; 39(11):1343-1354. PubMed ID: 34623625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
    Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US.
    Rosen VM; Taylor DC; Parekh H; Pandya A; Thompson D; Kuznik A; Waters DD; Drummond M; Weinstein MC
    Pharmacoeconomics; 2010; 28(1):47-60. PubMed ID: 20014876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
    Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
    Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
    Valentine WJ; Tucker D; Palmer AJ; Minshall ME; Foos V; Silberman C;
    Value Health; 2009; 12(1):1-9. PubMed ID: 18657104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
    Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
    Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.